Jódar, Esteban

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 6,900

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 868

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.

Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 639

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

Aroda, V. R., Ahmann, A., Cariou, B., Chow, F., Davies, M. J., Jódar, E., Mehta, R., Woo, V., & Lingvay, I. (2019) · Diabetes & Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 296

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Leiter, L. A., Bain, S. C., Hramiak, I., Jódar, E., Madsbad, S., Gondolf, T., Hansen, T., Holst, I., & Lingvay, I. (2019) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 159

Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes ( AWARD ‐9)

Pozzilli, P., Norwood, P., Jódar, E., Davies, M. J., Ivanyi, T., Jiang, H., Woodward, D. B., & Milicevic, Z. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 137

Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5

Wharton, S., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2023) · Obesity

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 124

Bone mass in androgen-insensitivity syndrome: response to hormonal replacement therapy.

Muñoz-Torres, M., Jódar, E., Quesada, M., & Escobar-Jiménez, F. (1995) · Calcified Tissue International

Sexual Differentiation and DisordersBone health and osteoporosis research

Cited by 81

Bone Changes in Pre- and Postmenopausal Women with Thyroid Cancer on Levothyroxine Therapy: Evolution of Axial and Appendicular Bone Mass

Jódar, E., Begoña López, M., García, L., Rigopoulou, D., Martínez, G., & Hawkins, F. (1998) · Osteoporosis International

Bone health and osteoporosis researchThyroid Disorders and Treatments

Cited by 59